220 related articles for article (PubMed ID: 17000698)
1. Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
Morales L; Paridaens R; Timmerman D; Neven P
Clin Cancer Res; 2006 Sep; 12(18):5603. PubMed ID: 17000698
[No Abstract] [Full Text] [Related]
2. Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399.
Paridaens R; Morales L; Neven P; Timmerman D
Ann Oncol; 2005 Aug; 16(8):1402-3; author reply 1402-3. PubMed ID: 15870087
[No Abstract] [Full Text] [Related]
3. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Morales L; Timmerman D; Neven P; Konstantinovic ML; Carbonez A; Van Huffel S; Ameye L; Weltens C; Christiaens MR; Vergote I; Paridaens R
Ann Oncol; 2005 Jan; 16(1):70-4. PubMed ID: 15598941
[TBL] [Abstract][Full Text] [Related]
4. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
[TBL] [Abstract][Full Text] [Related]
6. Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.
Morales L; Timmerman D; Neven P; Paridaens R
Int J Gynecol Cancer; 2006; 16 Suppl 2():515-7. PubMed ID: 17010061
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen and the uterus: an old drug tested by new modalities.
Achiron R; Grisaru D; Golan-Porat N; Lipitz S
Ultrasound Obstet Gynecol; 1996 May; 7(5):374-8. PubMed ID: 8774108
[TBL] [Abstract][Full Text] [Related]
8. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I
Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946
[TBL] [Abstract][Full Text] [Related]
9. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy.
McGonigle KF; Shaw SL; Vasilev SA; Odom-Maryon T; Roy S; Simpson JF
Am J Obstet Gynecol; 1998 Jun; 178(6):1145-50. PubMed ID: 9662294
[TBL] [Abstract][Full Text] [Related]
10. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of the endometrial pathology using flexible ambulatory hysteroscopy of patients treated with Tamoxifen].
Kuzmanov B
Akush Ginekol (Sofiia); 2004; 43(3):32-3. PubMed ID: 15341254
[TBL] [Abstract][Full Text] [Related]
12. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Garrone O; Bertelli G; Principe E; Lewis PD; Occelli M; Miraglio E; Merlano MC
Tumori; 2014; 100(6):620-4. PubMed ID: 25688495
[TBL] [Abstract][Full Text] [Related]
14. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen.
Salazar EL; Paredes A; Calzada L
Gynecol Endocrinol; 2005 Dec; 21(6):312-6. PubMed ID: 16390778
[TBL] [Abstract][Full Text] [Related]
15. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic evaluation of endometrial disease in postmenopausal patients with breast cancer and tamoxifen treatment.
Cohen I; Tepper R; Beyth Y
Am J Obstet Gynecol; 1999 Jan; 180(1 Pt 1):252. PubMed ID: 9914614
[No Abstract] [Full Text] [Related]
17. Tamoxifen induced endometrial abnormalities: evaluation by saline infusion sonohysterography.
Jaeger BM; Grumbach K
Md Med J; 1997 Sep; 46(8):433-5. PubMed ID: 9294952
[TBL] [Abstract][Full Text] [Related]
18. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
Cohen I
Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
[TBL] [Abstract][Full Text] [Related]
19. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study.
Achiron R; Lipitz S; Sivan E; Goldenberg M; Horovitz A; Frenkel Y; Mashiach S
Ultrasound Obstet Gynecol; 1995 Aug; 6(2):116-20. PubMed ID: 8535913
[TBL] [Abstract][Full Text] [Related]
20. Mitotically active leiomyoma of the uterus in a postmenopausal breast cancer patient receiving tamoxifen.
Liu IF; Yen YS; Cheng YM; Chou CY
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):167-9. PubMed ID: 17197361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]